Allstate reports second-quarter results on July 29 with short sellers pulling back and the stock trading near multi-month highs — setting up a debate about whether the recent re-rating has run ahead of the fundamentals.
The short-side pressure has eased materially into the print. Short interest has fallen roughly 15% over the past month to 3.0% of the free float, a level that puts shorts firmly in the background rather than the foreground. Borrow conditions confirm the picture: availability is extremely loose at roughly 1,870% — meaning the lending pool holds nearly 20 shares available for every one currently borrowed — and the cost to borrow remains negligible at around 0.5%. Options positioning is similarly relaxed, with the put/call ratio at 1.34, essentially in line with its 20-day average and carrying a z-score close to zero. The stock itself has been the stronger signal, gaining 12% over the past month to close at $259.97, with peers PGR, TRV, and CB all moving in the same direction but by smaller margins — Allstate's move stands out within the group.
The analyst community is split on whether the rally is justified. UBS moved to the sidelines earlier this month, downgrading to Neutral even while lifting its target to $261 — barely above the current price. That sets a ceiling in the eyes of one bellwether. JPMorgan took the opposite view, raising its target to $282 and maintaining Overweight, while Raymond James sits well above the crowd with a $300 target and a Strong Buy rating. The consensus mean target of around $255 now sits below where the stock is trading, which reflects how quickly the price has moved through the middle of the Street's range. Bulls point to recovering auto policies-in-force, favorable reserve development, and a combined ratio that recently printed a strong earnings beat of $3.41 per share against estimates. Bears flag the 89.4% combined ratio year-to-date as evidence of underwriting inefficiency versus the long-run target of 95%, and note that personal lines pricing pressure could squeeze margins if frequency trends worsen. Valuation is not obviously stretched — the trailing P/E sits near 8.9x and EV/EBITDA near 7.4x — but those multiples have drifted higher through July as the stock has rallied.
The ORTEX short score has eased steadily from 39.8 two weeks ago to 38.5 today, reflecting the broad pullback in short positioning and the loosening borrow market. The 90-day EPS momentum factor ranks in the 89th percentile, and the EPS surprise rank is in the 84th percentile — both consistent with a company that has been beating estimates with some regularity. Institutional holders have been broadly stable, with BlackRock adding over 1.1 million shares to a top position of 8.5% as of June 30, and Putnam building a more notable addition of 2.6 million shares in the same period. Insider activity over the past 90 days has been largely routine — compensation awards and small sales — with no signal of conviction buying or unusual selling from senior management.
The July 29 print will test whether the underwriting improvement that drove the recent beat can hold through a quarter that included elevated catastrophe activity, and whether management's tone on auto claims frequency gives the Street reason to revisit targets that the stock has already outrun.
See the live data behind this article on ORTEX.
Open ALL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
